Insights from the event
We joined global healthcare leaders in Glasgow for ISPOR Europe 2025, the premier conference in Europe for Health Economics and Outcomes Research (HEOR). As a proud ISPOR Mission Partner, we were thrilled to collaborate and advance the future of healthcare together.
Corporate partner insights interview by ISPOR
Harmonizing Health Technology Assessment: PICO consolidation under the EU HTA Regulation
The EU HTA regulation (EU HTAR) is reshaping global market access, bringing both opportunities and challenges for manufacturers. In this exclusive Corporate partner insights interview by ISPOR, Ruairi O'Donnell, Vice President of Market Access and Healthcare Consulting Europe at Cencora, joins Dr. Patty Peeples to explore how the industry can adapt to this new reality. Ruairi shares actionable strategies to navigate the complexities of EU HTA and PICO consolidation. From harmonizing clinical evidence across Europe to addressing unrealistic comparators and leveraging real-world evidence (RWE), this discussion provides a roadmap for success.
Poster presentation
Explore the groundbreaking research our experts presented during ISPOR Europe 2025! Our work spans a wide range of pressing healthcare topics, including global pricing dynamics, policy insights, cost-effectiveness evaluations, advancements in artificial intelligence, and health technology assessment (HTA) evolution. We also highlighted transformative solutions and the latest breakthroughs in health economics and outcomes research (HEOR). It’s an honor to contribute to these vital conversations and share our findings with the global community. The following PDFs are available in English only.
- The Artificial Intelligence Era in Health Economic Modeling
- Assessing Readiness for the EU-HTA Regulation: Insights from Market Access Experts Across Europe
Adapting to change: Analysis of trend estimation in AMNOG dossiers under revised G-BA guidelines
- Evaluating the effectiveness of interventions to reduce gender disparities in healthcare: An overview of literature reviews
- Global pricing meets domestic policy: Analyzing the financial impact of the most-favored nation approach on the United States’ medicine prices
- Hospital mortality in Germany – Analysis of German hospital data from 2000 to 2019
- Quality and impact of real-world data in chronic disease research: Insights from retrospective studies using the Hospital Episode Statistics (HES) database
- Trends in glucagon-like peptide-1 (GLP-1) receptor agonist prescribing in England: A data analysis using NHS prescription episodes statistics (PES)
- Utilization of real-world evidence (RWE) in AMNOG dossiers following the 2024 G-BA revision of module 3 requirements
- Unlocking insights in prescription data in England: The power of the prescribing episode statistics (PES) database
- Psychotropic medications for patients with treatment-resistant depression in France
- Balancing fit and accuracy: Evaluating survival model projections with immature data in health technology assessments
- Exploring Nordic real-world evidence sources for a PICO assessment of a hypothetical oncology drug and medical device product
- A comparative analysis of the Nordic market access pathways for medical devices
Cencora solution
EU Health Technology Assessment (HTA) consulting
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level.
Catch up on our latest insights
Trends Report
Unlock the future of market access in 2026: Cencora’s essential guide to navigating a shifting healthcare landscape
After a year of sweeping regulatory changes and shifting payer expectations, 2026 is poised to redefine market access for pharmaceutical manufacturers. Success will demand proactive strategies, organizational agility, and the smart application of emerging technologies to close data gaps and enhance communication. Download the report to learn more.
Article
HTA Quarterly Winter 2025
This edition features the conclusion of our three-part series on France’s Early Access Program (EAP), highlighting the potential of the National Health Database (SNDS) to streamline data collection and offering industry insights on enhancing the program. We also delve into the growing role of multilevel network meta-regression in health technology assessment (HTA), showcasing its ability to address challenges in comparing treatments with limited trial data. Lastly, we summarize findings from a study on leveraging Nordic real-world data to inform PICOs for Joint Clinical Assessments (JCAs), emphasizing the importance of proactive evidence generation and the unique value of Nordic health registries.
Connect with our team
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
